Market Cap: $453.52M
DI
DiaMedica Therapeutics Inc.
DMAC
NASDAQ (NASDAQ Capital Market)USD
Market Cap: $453.52M
DiaMedica Therapeutics Advances in Kidney Disease Treatment DiaMedica Therapeutics, a clinical-stage biopharmaceutical company, makes significant strides in the development of innovative treatments fo…
DiaMedica Therapeutics Advances in Kidney Disease Treatment DiaMedica Therapeutics is making significant strides in the treatment of kidney disease with its proprietary drug, DM199. The company recent…
DiaMedica Therapeutics Focuses on Advancing Kidney Disease Treatments DiaMedica Therapeutics, a clinical-stage biopharmaceutical company, is dedicated to developing innovative therapies for kidney dis…
DiaMedica Therapeutics Readies for Key Earnings Report Amid Promising Clinical Developments DiaMedica Therapeutics prepares to unveil its quarterly earnings report on November 12, 2025, a pivotal mome…
DiaMedica Therapeutics Poised for Critical Earnings Report Amid Promising Clinical Advances As DiaMedica Therapeutics approaches its quarterly earnings report scheduled for November 12, 2025, the comp…
DiaMedica Therapeutics Advances Toward Critical Earnings Report Amid Promising Trial Results DiaMedica Therapeutics is set to release its quarterly earnings report on November 12, 2025, a date that ho…
DiaMedica Therapeutics Advances in Neurological Drug Development DiaMedica Therapeutics announces significant progress in its clinical development of DM199, a recombinant human Dipeptidyl Peptidase I…
DiaMedica Therapeutics Advances Kidney Health Research with New Clinical Trial Initiative DiaMedica Therapeutics, a biopharmaceutical company focused on developing innovative treatments for kidney dis…
DiaMedica Therapeutics Prepares for Key Earnings Report Amidst Market Anticipation As DiaMedica Therapeutics (DMAC) approaches its quarterly earnings report scheduled for August 12, 2025, the biotechn…
DiaMedica Therapeutics Prepares for Crucial Earnings Report Amidst Market Anticipation As DiaMedica Therapeutics approaches the release of its quarterly earnings report on August 12, 2025, the biotech…
DiaMedica Therapeutics Prepares for Key Earnings Report Amidst Industry Developments DiaMedica Therapeutics (DMAC) stands on the brink of a significant moment as it prepares to release its quarterly e…
DiaMedica Therapeutics Prepares for Key Presentation on Innovative Ischemic Disease Treatments DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, is set to present at the Oppenhe…
DiaMedica Therapeutics Enhances Trial Protocol for Acute Ischemic Stroke DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company specializing in innovative therapies for severe ischemi…
DiaMedica Therapeutics Sets Stage for Innovative Treatments at Upcoming Conference DiaMedica Therapeutics Inc. engages in a critical endeavor aimed at revolutionizing the treatment landscape for sever…
### DiaMedica Therapeutics Advances in Ischemic Disease Treatments DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, announces its commitment to developing innovative therapies…